Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]

Aclaris Therapeutics (ACRS) FY Conference Summary Company Overview - Aclaris Therapeutics is an immuno-inflammatory R&D company with a focus on developing biologic drugs, particularly in dermatologic and respiratory indications [1][2][4]. Key Developments - Aclaris has undergone significant changes in the past year, including the acquisition of two assets, Sacatug and ATI-52, which are expected to enhance its pipeline [4][7]. - The company has three clinical assets currently in development: - IDKJAK3, which is completing an atopic dermatitis (AD) study and will move into alopecia areata later this year [5][6]. - TSLP antibody (Vosacutog), which has initiated a global Phase II trial [6]. - A bispecific antibody targeting TSLP and IL4R, cleared by the FDA, with a Phase I trial starting soon [6][12]. Pipeline and Clinical Trials - The TSLP antibody has shown a residence time of 400 hours on the target, significantly longer than competitors, which is crucial for neutralizing TSLP effectively [14][15]. - Aclaris aims to differentiate Vosacutog in the AD space, where it has shown promising early data, including a 94% EZ75 response rate in open-label trials [15][24]. - The company is also exploring respiratory indications, with data sharing rights from a Chinese partner conducting Phase II trials in severe asthma and chronic rhinosinusitis [21][26]. Strategic Focus - Aclaris is focusing on immuno-inflammatory diseases, particularly in dermatology and respiratory conditions, as part of its strategic direction [13][28]. - The decision to bifurcate development efforts between dermatology and respiratory indications is driven by the need for significant capital investment in later-stage respiratory studies, which Aclaris is currently not positioned to undertake alone [27][28]. Financial Position - Aclaris currently has over $190 million in cash, extending its runway through mid-2028, allowing it to pursue key catalysts in its pipeline [75][76]. - The company emphasizes a shareholder-friendly approach and efficient operational decisions to maintain financial health while advancing its clinical programs [75][76]. Future Outlook - Aclaris is optimistic about upcoming data readouts over the next 18 months, which are critical for the company's success [78][79]. - The company is also developing a discovery portfolio of biologic assets, indicating a commitment to innovation and long-term growth [11][12][79]. Conclusion - Aclaris Therapeutics is positioned to leverage its differentiated assets in the immuno-inflammatory space, with a strong focus on clinical development and strategic partnerships to enhance its market presence and drive future growth [76][78].